Physician profile
Ho Pak
NPI 1568426492
$752.74
in general payments reported to CMS, 2019-2025
13 companies · $153 in 2025
The $153 reported for 2025 was less than what a typical Surgery provider received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $111 · 2023: $125 · 2024: $364 · 2025: $153.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $641.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $641.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $136.87 | 2023-2025 | Calquence, Enhertu |
| Takeda Pharmaceuticals U.S.A., INC. | $118.06 | 2024-2025 | Fruzaqla, Alunbrig, Ninlaro |
| Boston Scientific Corporation | $99.53 | 2022-2025 | Wavewriter Alpha Prime 16 |
| Lilly USA, LLC | $90.99 | 2022-2024 | Verzenio, Mounjaro, Jardiance |
| Regeneron Healthcare Solutions, INC. | $56.90 | 2024-2025 | Libtayo |
| Incyte Corporation | $43.54 | 2024 | Jakafi, Pemazyre, Monjuvi |
| Mirati Therapeutics, INC. | $37.48 | 2023 | Krazati |
| Merck Sharp & Dohme LLC | $36.72 | 2024-2025 | Keytruda |
| Medtronic, INC. | $33.68 | 2022-2025 | Biosyn |
| Alexion Pharmaceuticals, INC. | $26.62 | 2025 | Ultomiris |
| Pfizer INC. | $25.88 | 2024 | |
| Sobi, INC | $25.86 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $20.61 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ho Pak listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.